JS Link

JS Link Long-term Debt

The Long-Term Debt of JS Link (127120.KQ) as of Oct 26, 2026 is 5.00 B KRW. In the previous year, Long-Term Debt was 934.61 M KRW — a change of 434.98% (higher).

Long-term Debt

5.00 BKRW

YoY

434.98%

Last updated:

Long-Term Debt of JS Link is 2025 5.00 B KRW. Long-Term Debt of JS Link was 2024 934.61 M KRW. It decreases by 434.98% higher compared to the previous year.

The JS Link Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
729.05 M KRW
Jan 1, 2019
537.00 M KRW
Jan 1, 2020
259.01 M KRW
Jan 1, 2021
81.20 M KRW
Jan 1, 2022
5.01 B KRW
Jan 1, 2023
3.03 B KRW
Jan 1, 2024
934.61 M KRW
Jan 1, 2025
5.00 B KRW
The JS Link Long-term Debt history
YEARLong-term DebtYoY
5.00 BKRW+434.98%
934.61 MKRW-69.16%
3.03 BKRW-39.54%
5.01 BKRW+6,072.63%
81.20 MKRW-68.65%
259.01 MKRW-51.77%
537.00 MKRW-26.34%
729.05 MKRW—
0.00KRW-100.00%
20.17 BKRW+8.07%
18.66 BKRW+92.06%
9.72 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JS Link Stock analysis

What does JS Link do? DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description. JS Link is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JS Link stock

Long-Term Debt of JS Link is 5.00 B KRW in 2025.

Long-Term Debt of JS Link changed from 934.61 M KRW to 5.00 B KRW, representing a 434.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt JS Link since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's JS Link historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JS Link

All Key Metrics — JS Link